Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 20, Number 6—June 2014


Adverse Pregnancy Outcomes and Coxiella burnetii Antibodies in Pregnant Women, Denmark

CME Logo

Medscape, LLC is pleased to provide online continuing medical education (CME) for this journal article, allowing clinicians the opportunity to earn CME credit.

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 70% minimum passing score and complete the evaluation at; (4) view/print certificate.

Release date: May 14, 2014; Expiration date: May 14, 2015

Learning Objectives

Upon completion of this activity, participants will be able to:

• Describe adverse outcomes of pregnancies with positive or increasing titers against C. burnetii, based on a case series from Denmark

• Distinguish the causal association between adverse pregnancy outcomes and C. burnetii infection

• Assess the overall risk for a Q fever–associated adverse pregnancy outcome.

CME Editor

Shannon O’Connor, ELS, Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: Shannon O’Connor has disclosed no relevant financial relationships.

CME Author

Laurie Barclay, MD, freelance writer and reviewer, Medscape, LLC. Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.


Disclosures: Stine Yde Nielsen, MD, PhD; Kåre Mølbak, MD, DMSc; Tine Brink Henriksen, PhD; and Karen Angeliki Krogfelt, PhD, have disclosed no relevant financial relationships. Carsten Schade Larsen, DMSc, has disclosed the following relevant financial relationships: served as a speaker or a member of a speakers bureau for GlaxoSmithKline, Gilead; received grants for clinical research from CSL Behring. Steen Villumsen, MD, PhD, has disclosed the following relevant financial relationships: served as an advisor or consultant for and received grants for clinical research from Statens Serum Institut.


Article Navigation